PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc. (PTCT)

Market Closed
16 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS)
$
59. 24
-1.75
-2.8693%
$
5.4B Market Cap
- P/E Ratio
- Div Yield
789,000 Volume
-5.84 Eps
$ 60.99
Previous Close
Add Transaction
Day Range
58.98 61.73
Year Range
58.8 90.87
Want to track PTCT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 8 months ago
PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seekingalpha | 9 months ago
PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seekingalpha | 10 months ago
PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript

PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript

PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript

Seekingalpha | 10 months ago
PTC Therapeutics, Inc. (PTCT) Presents at UBS Global Healthcare Conference 2025 Transcript

PTC Therapeutics, Inc. (PTCT) Presents at UBS Global Healthcare Conference 2025 Transcript

PTC Therapeutics, Inc. ( PTCT ) UBS Global Healthcare Conference 2025 November 11, 2025 3:30 PM EST Company Participants Matthew Klein - CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.

Seekingalpha | 11 months ago
PTC Therapeutics, Inc. (PTCT) Q3 2025 Earnings Call Transcript

PTC Therapeutics, Inc. (PTCT) Q3 2025 Earnings Call Transcript

PTC Therapeutics, Inc. ( PTCT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Ellen Cavaleri Matthew Klein - CEO & Director Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Tazeen Ahmad - BofA Securities, Research Division Brian Abrahams - RBC Capital Markets, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Judah Frommer - Morgan Stanley, Research Division Yuxi Dong - Jefferies LLC, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Joon Lee - Truist Securities, Inc., Research Division Huidong Wang - Barclays Bank PLC, Research Division Samantha Corwin - William Blair & Company L.L.C., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division John Peyton Bohnsack - TD Cowen, Research Division Luke Herrmann - Robert W.

Seekingalpha | 11 months ago
Compared to Estimates, PTC Therapeutics (PTCT) Q3 Earnings: A Look at Key Metrics

Compared to Estimates, PTC Therapeutics (PTCT) Q3 Earnings: A Look at Key Metrics

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 11 months ago
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates

PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates

PTC Therapeutics (PTCT) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of a loss of $1.19 per share. This compares to a loss of $1.39 per share a year ago.

Zacks | 11 months ago
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 11 months ago
PTC Therapeutics, Inc. (PTCT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

PTC Therapeutics, Inc. (PTCT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst All right. Welcome, everyone, to this session of the Morgan Stanley Global Healthcare Conference.

Seekingalpha | 1 year ago
PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript

PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Corporate Participant Eric Pauwels - Chief Business Officer Jarwei Fang - Corporate Participant Matthew B. Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Dingding Shi - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jenny Leigh Gonzalez-Armenta - Leerink Partners LLC, Research Division John Peyton Bohnsack - TD Cowen, Research Division Joon So Lee - Truist Securities, Inc., Research Division Judah C.

Seekingalpha | 1 year ago
PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say

PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 1 year ago
Loading...
Load More